According to Canadian guidelines, which statin is the preferred high‑intensity agent for primary and secondary cardiovascular prevention?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 13, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Which Statin is Best According to Canadian Guidelines

The 2021 Canadian Cardiovascular Society guidelines recommend high-intensity statin therapy as the preferred first-line agent for both primary and secondary cardiovascular prevention, without specifying a single "best" statin—the focus is on achieving high-intensity lipid lowering rather than selecting a particular agent. 1

High-Intensity Statin Therapy Framework

The Canadian approach prioritizes intensity of LDL-C reduction over specific statin selection. 1 High-intensity statins are defined as those capable of reducing LDL-C by ≥50%, which typically includes:

  • Atorvastatin 40-80 mg
  • Rosuvastatin 20-40 mg

These are the two statins that consistently achieve high-intensity lipid lowering in clinical practice. 1

Secondary Prevention: The Strongest Recommendation

For all patients with established cardiovascular disease, high-intensity statin therapy is strongly recommended in addition to health behavior modifications (Strong Recommendation). 1 This represents the cornerstone of lipid management in secondary prevention. 1

When High-Intensity Statins Are Not Tolerated

If patients cannot tolerate high-intensity statins, the guidelines recommend using maximally tolerated statin doses and then applying specific thresholds for intensification with additional therapies. 1 The sequential approach is:

  1. Maximize statin dose tolerance first
  2. Add ezetimibe if LDL-C remains ≥1.8 mmol/L 1
  3. Add PCSK9 inhibitors (evolocumab or alirocumab) if LDL-C remains ≥1.8 mmol/L despite ezetimibe 1

Primary Prevention Considerations

While the guidelines emphasize high-intensity statins for secondary prevention most strongly, the Canadian approach to primary prevention also favors moderate to high-intensity statins based on calculated cardiovascular risk. 2 The CCS guidelines demonstrate high sensitivity (68%) for identifying individuals who will develop ASCVD events, making them effective for primary prevention statin allocation. 2

Practical Algorithm for Statin Selection

Step 1: Determine if patient requires primary or secondary prevention

Step 2: For secondary prevention:

  • Start atorvastatin 40-80 mg or rosuvastatin 20-40 mg 1
  • If intolerant, use maximally tolerated dose of any statin 1

Step 3: Assess LDL-C response after 8-12 weeks

Step 4: If LDL-C ≥1.8 mmol/L on maximally tolerated statin:

  • Add ezetimibe 10 mg daily 1
  • Reassess in 8-12 weeks

Step 5: If LDL-C remains ≥1.8 mmol/L:

  • Add PCSK9 inhibitor (evolocumab or alirocumab) 1
  • Prioritize PCSK9 inhibitors first (without ezetimibe) in very high-risk patients including those with recent ACS, polyvascular disease, or multiple risk enhancers 1

Critical Caveats

Cost and access limitations significantly affect PCSK9 inhibitor use in Canada, as provincial drug plan coverage varies widely. 1 Shared decision-making regarding out-of-pocket costs is essential before prescribing these agents. 1

No down-titration required: If intensive lipid-lowering therapy results in very low LDL-C levels, dose reduction is generally not necessary, as trials show no safety concerns with very low LDL-C levels. 1

The "best" statin is the one that achieves high-intensity LDL-C reduction and is tolerated by the patient—this is typically atorvastatin 40-80 mg or rosuvastatin 20-40 mg in the Canadian context. 1

References

Related Questions

What is the recommended approach to initiating statin therapy, including initial dose, baseline labs, monitoring, and dose adjustment?
How should I treat a patient with total cholesterol of about 340 mg/dL, LDL cholesterol of about 309 mg/dL, diabetes mellitus, and obesity?
According to the American Diabetes Association, what is the LDL‑cholesterol target for an adult with diabetes who has no known coronary artery disease?
What considerations should be taken into account when prescribing statins to patients older than 78 years?
What are the guideline-recommended non‑HDL cholesterol target levels and treatment approach for preventing cardiovascular disease in adults based on risk categories?
In a stable patient with atrial fibrillation on metoprolol (beta‑blocker) and rivaroxaban (Xarelto), who is asymptomatic with a ventricular rate of 70 beats per minute, is an irregularly irregular rhythm expected and does it require any intervention?
Can idiopathic intracranial hypertension (IIH) occur concurrently with uveitis?
What is a primary (Ghon) complex in tuberculosis and how is it managed?
A patient with a squamous‑cell carcinoma lesion who had cellulitis treated two months ago now shows recurrent infection; can I prescribe another course of cephalexin (Keflex)?
What is the recommended management for an undescended testis in a newborn male?
What is the recommended evaluation and management for a patient with a gallbladder hematoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.